Interaction study between rtPA and bevacizumab.
Faure
Céline
C
Macrez
Richard
R
Vivien
Denis
D
Sahel
José-Alain
JA
Bonnel
Sébastien
S
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000378:metabolism*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004338:Drug Combinations; D004347:Drug Interactions; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D012166:Retinal Hemorrhage / Q000517:prevention & control; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004338:Drug Combinations; D000068258:Bevacizumab; D010959:Tissue Plasminogen Activator